Sandrine Macé

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 620 citations

Hematological Malignancy, Medicine, Immunology +6

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 366 citations

Hematological Malignancy, Relapsed Multiple Myeloma, Medicine +11

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu et al. · New England Journal of Medicine · 2024 · 198 citations

The Determinants of Pre- and Postpromotion Dips in Sales of Frequently Purchased Goods

Sandrine Macé, Scott A. Neslin · Journal of Marketing Research · 2004 · 151 citations

Marketing Analytics, Universal Product Code, Consumer Research +16

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Maja J.A. de Jonge, Vincent A. de Weger, Mark A. Dickson et al. · European Journal of Cancer · 2017 · 124 citations

Oncology, Medicine, Solid Tumours +7